G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$2.99 USD
+0.11 (3.82%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $3.00 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 321 - 340 ( 353 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics 3Q18 Results; Several Milestones Coming Before Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Small Cell Update Confirms Multi-Lineage Preservation, Trend to PFS Improvement
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics Presents Positive Phase 2 Trilaciclib Data in SCLC at ESMO; PT Adjusted
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology -ESMO 2018 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
G1 Therapeutics to Present Posters at ESMO on Trilaciclib in First-line SCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Protocol Amendment to Ph 2 Trila Triple Combo Study Could Add to Filing
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Therapeutics Plans Expedited Analysis of Trilaciclib Phase 2 in SCLC; Raising Price Target to $79
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Therapeutics Takeaways, CDK4/6i Platform Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Positive Sentiment Going into Q4 Data Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Therapeutics 2Q18 Results and Pipeline Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Promising Preliminary G1T38 Phase 1b Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Biotechnology -ASCO Presentations Roundup for Covered Companies: Part 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Unclassified
G1 Could Become Number One in the CDK4/6 Market; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Unclassified
Company: G1 Therapeutics
Industry: Unclassified
Rest of Pipeline Comes into View as Trilaciclib Regulatory Timeline Accelerates
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D